Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Global X S&P 500 U.S. Market Leaders Top 50 ETF (NY:FLAG)

27.48 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Global X S&P 500 U.S. Market Leaders Top 50 ETF

News headline image
Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
From First Light Acquisition Group
Via GlobeNewswire
News headline image
First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments
From First Light Acquisition Group
Via GlobeNewswire
News headline image
FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET
From First Light Acquisition Group
Via GlobeNewswire
News headline image
FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET
From First Light Acquisition Group
Via GlobeNewswire
News headline image
Flag Stockholders: Reminder to Vote for Proposed Business Combination
From First Light Acquisition Group
Via GlobeNewswire
News headline image
First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination
From First Light Acquisition Group
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
From Calidi Biotherapeutics, Inc.
Via Business Wire
News headline image
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
Financing led by Jackson Investment Group (JIG) with participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi Biotherapeutics,... 
From First Light Acquisition Group; Caldi Biotherapeutics
Via GlobeNewswire
News headline image
Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
From First Light Acquisition Group; Calidi Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
First Light Acquisition Group, Inc. Announces Approval of Extension Amendment to Certificate of Incorporation
From First Light Acquisition Group
Via GlobeNewswire
News headline image
CORRECTION - First Light Acquisition Group, Inc. Transfers Listing to NYSE American LLC
From First Light Acquisition Group
Via GlobeNewswire
News headline image
First Light Acquisition Group, Inc. Transfers Listing to NYSE American LLC
From First Light Acquisition Group
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.